Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Patient enrollment completed in a clinical trial with Progenta in uterine fibroids

Sep. 17, 2004

BMS scientists design novel thyroid receptor agonists for obesity, skin disorders, etc.

Sep. 17, 2004

New RXR agonists prepared and tested by Allergan researchers

Sep. 17, 2004

Therapeutic effects of DPP-IV inhibition with LAF-237 in patients with type 2 diabetes

Sep. 17, 2004

Research in stimulating immune responses of juvenile diabetics

Sep. 17, 2004

Sangamo updates ZFP programs

Sep. 16, 2004

Novel PTP inhibitors covered by Procter & Gamble patent

Sep. 16, 2004

Effects of beta3-adrenoceptor agonist KTO-7924 on insulin secretion and adipose tissue

Sep. 16, 2004

New data on the therapeutic benefits of exenatide in diabetes

Sep. 15, 2004

Novel glucagon receptor antagonist by Boehringer Ingelheim

Sep. 15, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...